BiotechTube

LY2189265 + Exenatide + Placebo + Metformin + Pioglitazone

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 2

Conditions

Diabetes Mellitus, Type 2

Trial Timeline

Feb 1, 2010 → May 1, 2012

NCT ID
NCT01064687

About LY2189265 + Exenatide + Placebo + Metformin + Pioglitazone

LY2189265 + Exenatide + Placebo + Metformin + Pioglitazone is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT01064687. Target conditions include Diabetes Mellitus, Type 2.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01064687Phase 3Completed

Competing Products

20 competing products in Diabetes Mellitus, Type 2

See all competitors
ProductCompanyStageHype Score
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
77
MKP10241 + PlaceboMankind PharmaPhase 2
52
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
33
LY3209590 + Insulin DegludecEli LillyPhase 1
33
AC2993Eli LillyPhase 3
77
LY3209590 + PlaceboEli LillyPhase 1
33
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
77
LY2963016 + LantusEli LillyPhase 1
33
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
23
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
85
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
77
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
36
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
33
Placebo + LinagliptinEli LillyPhase 3
77
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
85
teplizumab or placeboEli LillyPhase 1
33
LY2428757 + PlaceboEli LillyPhase 2
52
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
77
LY900014 (SC) + LY900014 (IV)Eli LillyPhase 1
33

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85